ADT1634-Telazorlimab Biosimilar-(TNFRSF4/OX40/CD134)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1634 |
Product Name |
ADT1634-Telazorlimab Biosimilar-(TNFRSF4/OX40/CD134)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse OX40 antibody, anti-OX40 antibody, anti OX40 antibody, recombinant CD134, CD134 antibody, anti-CD134 monoclonal antibody, TNFRSF4 antibodies, TNFRSF4 recombinant antibody, TNFRSF4 blocking antibody, CD134 recombinant antibody, CD134 blocking antibody |
|
Host |
CHO Cells |
Species |
Mouse |
Target |
TNFRSF4/OX40/CD134 |
Gene ID |
22163 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Immunology |
CAS Number |
2126777-87-3 |
Product Description |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (telazorlimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is kappa. It has a predicted MW of 145.5 kDa. |
Molecular Weight |
145.5 KDa |
Application |
ELISA, Flow Cytometry, Kinetics (BLI), Kinetics (SPR), Functional assay |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH6 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Sato, Y., et al. (2013). “OX40 signaling in T cells: a potential target for cancer immunotherapy.” Cancer Science, 104(5), 563-570.
2. Zhang, Y., et al. (2015). “The role of OX40 in the regulation of immune responses.” Nature Reviews Immunology, 15(1), 1-12.
3. Fisher, T. S., et al. (2009). “OX40: a new target for cancer immunotherapy.” Clinical Cancer Research, 15(20), 6350-6356.
|